1	Study protocol for a pilot clinical trial to understand neural mechanisms of response to a
2	psychological treatment for pain and anxiety in pediatric functional abdominal pain
3	disorders (FAPD)
4	Authors: Natoshia R. Cunningham <sup>1,2*</sup> , Michelle A. Adler <sup>1,2</sup> , Brittany N. Barber Garcia <sup>2,3</sup> , Taylor
5	Abounader <sup>4</sup> , Alaina K. Miller <sup>4</sup> , Mariela Monzalvo <sup>4</sup> , Ismaeel Hashemi <sup>5</sup> , Ryan Cox <sup>2,6</sup> , Samantha
6	L. Ely <sup>7</sup> , Yong Zhou <sup>8</sup> , Mark DeLano <sup>8,9</sup> , Todd Mulderink <sup>8,9</sup> , Mathew J. Reeves <sup>10</sup> , James L.
7	Peugh <sup>11,12</sup> , Susmita Kashikar-Zuck <sup>11,12</sup> , Robert C. Coghill <sup>11,12</sup> , Judith E. Arnetz <sup>1,2</sup> , David C. Zhu <sup>9</sup>
8	
9	<sup>1</sup> Department of Family Medicine, Michigan State University, Grand Rapids, Michigan, USA
10 11	<sup>2</sup> College of Human Medicine, Michigan State University, Grand Rapids, Michigan State University, Grand Rapids, Michigan, USA
12	<sup>3</sup> Helen DeVos Children's Hospital Pediatric Behavioral Health, Grand Rapids, Michigan, USA
13	<sup>4</sup> School of Professional Psychology, Wright State University, Dayton, Ohio, USA
14	<sup>5</sup> Department of Pediatric Gastroenterology, Novant Health, North Carolina, USA
15	<sup>6</sup> Helen DeVos Children's Hospital Pediatric Gastroenterology, Grand Rapids, Michigan, USA
16 17	<sup>7</sup> Department of Psychiatry and Behavioral Neuroscience, Wayne State University, Detroit, Michigan, USA
18	<sup>8</sup> Corewell Health Radiology, Grand Rapids, Michigan, USA
19 20	<sup>9</sup> Department of Radiology, College of Human Medicine, Michigan State University, Grand Rapids, Michigan, USA
21 22	<sup>10</sup> Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, Michigan, USA
23	<sup>11</sup> Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA
24 25	<sup>12</sup> Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
26	*Corresponding author: natoshia@msu.edu
27	All authors had a substantive role in manuscript completion.

2	o
2	ō.

#### Abstract

29	Background. Functional abdominal pain disorders (FAPD) are the most common chronic pain
30	conditions of childhood and are made worse by co-occurring anxiety. Our research team found
31	that the Aim to Decrease Pain and Anxiety Treatment (ADAPT), a six-session coping skills
32	program using cognitive behavioral therapy strategies, was effective in improving pain-related
33	symptoms and anxiety symptoms compared to standard care. In follow-up, this current
34	randomized clinical trial (RCT) aims to test potential neural mechanisms underlying the effect of
35	ADAPT. Specifically, this two-arm RCT will explore changes in amygdalar functional
36	connectivity (primary outcome) following the ADAPT protocol during the water loading
37	symptom provocation task (WL-SPT). Secondary (e.g., changes in regional cerebral blood flow
38	via pulsed arterial spin labeling MRI) and exploratory (e.g., the association between the changes
39	in functional connectivity and clinical symptoms) outcomes will also be investigated.
40	Methods. We will include patients ages 11 to 16 years presenting to outpatient pediatric
41	gastroenterology care at a midwestern children's hospital with a diagnosis of FAPD plus
42	evidence of clinical anxiety based on a validated screening tool (the Generalized Anxiety
43	Disorder-7 [GAD-7] measure). Eligible participants will undergo baseline neuroimaging
44	involving the WL-SPT, and assessment of self-reported pain, anxiety, and additional symptoms,
45	prior to being randomized to a six-week remotely delivered ADAPT program plus standard
46	medical care or standard medical care alone (waitlist). Thereafter, subjects will complete a post
47	assessment neuroimaging visit similar in nature to their first visit.
48	Conclusions. This small scale RCT aims to increase understanding of potential neural

49 mechanisms of response to ADAPT. ClinicalTrials.gov registration: NCT03518216

50

51

#### 52 1.1. Background

#### Introduction

Functional abdominal pain disorders (FAPD) are among the most common chronic pain 53 54 conditions impacting children and adolescents. These complex pain conditions are thought to result from dysregulations in the brain-gut axis and are characterized by aberrant amygdalar 55 functional connectivity patterns when experiencing pain during a water loading symptom 56 provocation task (WL-SPT), and at rest when compared to healthy youth [1]. The prevalence of 57 such conditions ranges from 4% to 41% globally and the median rate is approximately 12% [2]. 58 These conditions account for 50% of all pediatric gastroenterology (GI) visits [3]. One third of 59 youth with FAPD experience impairment over the long term (e.g., for five years or more) [4], 60 and impairment may be more pronounced in adolescent versus pre-adolescent vouth [5]. 61 62 Anxiety is also very common in youth with FAPD, with prevalence between 42% to 85% [5-7]. Youth with FAPD and comorbid anxiety have greater rates of pain-related impairment [8] and 63 higher pain intensity [5]. Those who have elevated levels of anxiety, pain and disability are at 64 65 risk for persistently elevated disability [8]. Further, youth with chronic pain conditions such as FAPD and comorbid anxiety are less likely to respond to cognitive behavioral therapy for pain 66 management, the current gold standard for care [9]. 67

To improve outcomes for youth impacted by FAPD and comorbid anxiety, the study PI and her team developed an enhanced approach to care, called the Aim to Decrease Anxiety and Pain Treatment (ADAPT) [10]. ADAPT is a six-session, individually delivered protocol that targets pain and anxiety through a blend of live and web-based sessions drawn from cognitive behavioral therapy [11, 12] and in the current study have also been infused with mindfulness meditation approaches [13]. ADAPT was found to be superior in reducing symptoms of

74 functional disability and anxiety in youth with FAPD in a randomized clinical trial as compared to standard medical treatment alone [14]. Although the study team has previously found 75 evidence of aberrant functional connectivity in the brains of youth with FAPD [1] (during the 76 WL-SPT and when compared to the brains of healthy youth), the potential neural correlates 77 underlying effective *treatments* for these conditions are unknown. This is important because it 78 79 allows us to understand whether an effective nonpharmacologic treatment for pain and anxiety impacts neurological functioning in youth with FAPD. Here we report the protocol for a 80 randomized trial designed to investigate the potential neural mechanisms associated with the 81 82 treatment effect of ADAPT.

#### 83 1.2. Study aims and hypotheses

The goal of this randomized controlled trial (RCT) is to investigate potential neural 84 mechanisms underlying the treatment effect of ADAPT. Specifically, it is hypothesized that 85 ADAPT will correspond to the normalization of hyperactive functional connectivity patterns 86 (following at WL-SPT and at rest) between the amygdala and other regions implicated in pain as 87 compared to those undergoing standard care/waitlist control condition. Secondarily, we propose 88 that regional cerebral blood flow (CBF) observed via 3D Pulsed Arterial Spin Labeling (PASL) 89 MRI will be reduced following ADAPT versus standard care/waitlist (after the WL-SPT and at 90 rest). Lastly, reductions in functional connectivity and regional CBF will correspond to 91 reductions in child-reported pain intensity and unpleasantness symptoms. This paper details the 92 study protocol of this clinical trial, NCT03518216, funded by a National Center for 93 Complementary and Integrative Health/National Institutes of Health (NCCIH/NIH) K23 grant, 94 95 AT009458.

96	Primary Outcomes. Aim 1a. Left amygdala-prefrontal cortex (AMY-PFC) functional
97	connectivity will be significantly reduced (i.e., evidence of decreased hyperconnectivity) after
98	the WL-SPT post ADAPT vs. waitlist. Aim 1b. Changes between both the left and right
99	amygdala and other network regions (e.g., thalamus) that are implicated in pain processing (e.g.,
100	default mode network [1, 15-18]) following ADAPT versus waitlist will also be investigated via
101	a whole brain search. This includes changes following the WL-SPT and differences during rest
102	between the ADAPT and waitlist groups.
103	Secondary Outcomes (Aim 2): To assess if regional CBF reduction is associated with
104	cognitive (e.g., prefrontal cortex [PFC]), affective (e.g., pregenual anterior cingulate cortex
105	[pgACC], amygdala [AMY]), and visceral afferent (e.g., insula [INS], thalamus, anterior mid-
106	cingulate cortex [aMCC], S1 & S2) pain. It is hypothesized that regional CBF associated with
107	cognitive, affective, and visceral afferent pain will be significantly reduced (following the WI-
108	SPT and at rest) after ADAPT vs. waitlist.
109	Exploratory Outcomes: To assess if changes in functional connectivity and brain
110	activations following ADAPT will correspond to reductions in pain (intensity and
111	unpleasantness) and anxiety ratings. Our previous research has indicated amygdalar functional
112	connectivity changes in youth with FAPD undergoing water loading are evident when
113	accounting for changes in pain intensity and pain unpleasantness [1].
114	As noted below, additional measures of psychosocial factors (e.g., anxiety, pain
115	catastrophizing, adverse childhood experiences), physical impairment (e.g., functional disability,
116	pain interference) and sociodemographic data will also be collected.

1	1	7
1	- 1	1

#### Methods

#### 118 2.1. Study design and setting

119 The current study is a masked and mechanistic pilot clinical trial. The primary study site 120 (Michigan State University [MSU], led by NRC) will coordinate the study activities. Any 121 modifications will be communicated with IRB, study team, data monitoring committee, and the

122 NCCIH as appropriate.

Study recruitment of male and female youth will take place in outpatient pediatric 123 gastroenterology clinics at Helen DeVos Children's Hospital/ (HDVCH)/Corewell Health. In-124 person and virtual recruitment will be utilized depending on whether the patient presents to clinic 125 126 in person or virtually (see section 2.3 Study Procedures for more details). Patients diagnosed with FAPD by the medical team who agree to participate will complete additional screening 127 measures to assess subject eligibility (see section 2.2. Eligibility criteria for more details). 128 Qualifying participants will complete two neuroimaging assessments with surveys 129 (baseline and post, approximately 8 weeks part) (see Fig 1) at an outpatient imaging clinic at a 130 satellite location of Corewell Health where the study scanner is located (approximately 15 131 minutes from the main children's hospital). 132

Fig 1. Schedule of Enrollment, Interventions, and Assessments. SPIRIT schedule ofparticipation.

Following the baseline assessment, participants will be randomized to ADAPT or waitlist using a concealment method by a staff external to the study team (see section *2.4 Randomization*). The outcome assessor, study PI and study statisticians will be blinded to participant randomization. The blind will be broken at the clinical discretion of the supervising

psychologist (BBG). Circumstances for breaking the blind may include cases when a patient's safety is at risk, differential attrition, or if a patient's symptoms remarkably worsen throughout treatment. If the blind needed to be broken, the study team would communicate with the local IRB, any NCCIH members involved in the study, and involve our study team, included but not limited to the PI, co-mentors, the biostatistician, and the outcome accessors (post-baccalaureate research coordinator).

The ADAPT program (see section 2.6 Intervention for more details) will be delivered
virtually by a trained psychological provider (advanced doctoral students of pediatric psychology
(TA, AM, MM)) under the supervision of a licensed clinical pediatric pain psychologist (BBG).
Of note, live portions of the original ADAPT protocol were originally delivered in-person,
however, due to COVID-19, we will deliver those portions of ADAPT using HIPAA compliant
Zoom videoconferencing.

The target population is male and female youth between the ages of 11-16 with functional abdominal pain disorders (FAPD) and clinically significant anxiety based on the Generalized Anxiety Disorder-7 [GAD-7] [19] measure with a total cut-off score  $\geq$  10; (see section 2.5. *Assessments & Outcome Measures* for additional details). We aim to have between 17–25 participants in each arm for a total N of 34-50 participants in the study. Gender and age will be used as blocking variables in randomization (see more details in section 2.4 *Randomization*).

We plan to approach approximately 124 participants, ages 11-16 years. Of those, we expect 75% will agree to participate (n=93) based on our pilot functional magnetic resonance imaging (fMRI) study [10]. Of those, we expect approximately 65% will qualify. Thus, we anticipate recruiting n=60 to complete a baseline assessment. Based on our previous RCT, we expect 85% of those recruited will complete the baseline assessment (n = 50) and the majority

162	will be retained in the study (90%, n=45). Based on our fMRI pilot study, we expect to lose
163	approximately 10% of participant data to movement artifacts yielding n=40 with usable data.
164	This study is approved by Michigan State University's institutional review board, (IRB),
165	STUDY00003419, with Helen DeVos Children's Hospital/Corewell Health relying on the
166	primary IRB.

#### 167 2.2. Eligibility criteria

168 *Inclusion criteria* will include children who must: 1) be between 11 and 16 years of age 169 and their parent/primary caregiver will participate in the study; 2) meet criteria for FAPD based on physician/nurse practitioner diagnosis of FAPD and ROME IV FAPD criteria [20, 21] (see 170 171 section 2.5. Assessments & Outcome Measures for additional details); 3) meet criteria for presence of clinical anxiety (based on the Generalized Anxiety Disorder-7 [GAD-7] [19] 172 measure with a total cut-off score  $\geq 10$ ; (see section 2.5. Assessments & Outcome Measures for 173 additional details)) or a current diagnosis of an anxiety disorder as indicated in the patient 174 electronic medical record; 4) have sufficient English language ability (along with their caregiver) 175 necessary to complete the study measures and protocol. 176 *Exclusion criteria* will include patients with: 1) a significant medical condition(s) with an 177

identifiable organic cause including those that may include abdominal pain symptoms (e.g., 178

Inflammatory Bowel Diseases); 2) a documented developmental delay(s), autism spectrum 179

disorder, a previously diagnosed thought disorder (i.e., psychosis), or bipolar disorder; 3) 180

significant visual, hearing, or speech impairment; organic brain injury; 4) current psychological 181

- 182 therapy for pain or anxiety; 5) depressive symptoms cut-off score  $\geq 22$  on the Patient Health
- Questionnaire-9 [PHQ-9] [22] (see section 2.5. Assessments & Outcome Measures for additional 183

details), or current active suicidal ideation; 6) an implant such as a cochlear implant device, a
pacemaker or neurostimulator containing electrical circuitry or generating magnetic signals.
Participants with 7) any significant ferrous material in their body that could pose the potential for
harm in the MRI environment or cause signal dropout in key brain regions (i.e. orthodontia); 8)
reported current/suspected pregnancy; 9) evidence of claustrophobia; 10) inability or
unwillingness of individual or legal guardian/representative to give written informed consent.

#### 190 *2.3. Study procedures*

Eligible participants with FAPD will be identified for the study from new or existing 191 patients seen at the outpatient pediatric GI clinics. The lead GI care provider (e.g., physician, 192 nurse practitioner) will confirm that identified patients meet criteria for FAPD, introduce the 193 194 study, and then study staff will speak with the family to provide additional details and obtain verbal and written consent (caregiver) and assent (youth participant). If study staff are not 195 physically present (i.e., if the GI visit occurs via telehealth, or if study staff are unable to attend 196 197 the GI visit), virtual consent procedures will be conducted via phone and Research Electronic Data Capture (REDCap) eConsent Framework to minimize patient risk (includes written 198 consent). Written consent will be obtained from the participating caregiver, and written assent 199 will be obtained from the participating child. After consent is obtained, study staff will conduct a 200 psychosocial screening to determine eligibility if screening was not performed as part of the 201 clinic visit (e.g., anxiety and depressive symptom screening); (see section 2.5. Assessments & 202 Outcome Measures and Fig 2 for additional details). Of note, the HDVCH/Corewell healthcare 203 system routinely screens patients for anxiety and depression using the PHQ-4 [23] as part of 204 205 standard medical care, with the GAD-7 [19] and PHQ-9 [22] subsequently administered for those who endorse anxiety or depressive symptomatology. Even if children do not endorse symptoms 206

on the PHQ-4, the research team will administer the GAD-7 and PHQ-9 to interested and
potentially eligible participants following the consenting process.

Fig 2. Referral, screening, and enrollment procedure. The medical provider will confirm
patient diagnosis of FAPD and introduce the study. If a patient is interested, the research
assistant will follow-up with the patient and caregiver (in-person at the clinic visit or via phone).
The research assistant will perform consent procedures and complete screening measures that
were not a part of the patients' medical visit. After eligibility screening, the patient will be
enrolled.

Potentially eligible participants will also be screened for MRI eligibility (e.g., to rule out 215 claustrophobia and presence of metal in the body). Enrolled patients will then be scheduled for 216 217 their MRI visits, approximately 8 weeks apart (see Fig 3). For participating, youth will receive up to \$200 in Amazon gift cards (\$100 at baseline and \$100 at the post assessment). If a 218 participant elects not to complete ADAPT, they are still eligible to complete the post-assessment. 219 220 Fig 3. Study timeline. Participants will be screened and if eligible, will be scheduled for a baseline assessment. Following the baseline visit, participants will be randomized to either 221 ADAPT or a waitlist control group. Participants will complete a post assessment ~7-9 weeks 222 from the baseline assessment. Participants who are part of the waitlist control group will be 223 offered ADAPT following their post assessment as a clinical courtesy, which is detailed in the 224 225 consent process.

226 2.4. Randomization

Following the baseline visit, MRI images will be reviewed by a radiologist (TM, MD) for safety.
Assuming no incidental findings which would preclude participation are present, participants

will be randomized. Randomization will be generated using PROC PLAN in SAS 9.3 by an 229 external team member. Gender and age will be used as blocking variables in randomization. The 230 randomizer will not have access to the data. The randomization schedule and code sheet will be 231 held confidentially by a designated secondary research team member not involved in data 232 collection, and the study interventionist will contact the designee to get the next assignment 233 234 when a participant is enrolled in the study. The outcome assessor, study PI, and study statistician will be blinded to participant randomization. Patients and their families will be informed of 235 group assignment within one week of their baseline assessment and begin ADAPT or waitlist 236 237 approximately one week after group assignment.

#### 238 2.5. Assessments & Outcome Measures

As noted above, qualifying participants and their respective caregivers will be invited to 239 attend an in-person baseline assessment with neuroimaging. Neuroimaging sequences will be 240 used to assess the primary and secondary outcomes. Participants will complete some additional 241 study measures (see below). Caregivers will complete several measures pertaining to their 242 child's pain and child's worries in addition to a measure of their own psychological symptoms. 243 To minimize burden, participants and caregivers will be given the option to either complete the 244 majority of measures up to 5 days before this visit using their own electronic device (to reduce 245 the length of the in-person visit; see details below). 246

Psychometrically validated instruments (self-report unless otherwise indicated) sensitive to change in pediatric health studies will be used. All assessments will be delivered directly to participants and caregivers and collected via autonomous self-report in REDCap, either during the in-person neuroimaging study visits or 1-5 days beforehand. The research coordinator will

251	oversee data collection to ensure data is complete and collected in a timely manner. The study
252	coordinator performing outcome assessments will be blinded to group assignment.

During the neuroimaging portion of the assessment, participants will use a sliding scale to report their current pain intensity, pain unpleasantness, and anxiety. Specifically, participants will enter the MRI scanner, where scans of brain structures and cerebral blood flow will be performed while participants provide current pain and anxiety ratings (~25 minutes). Participants will then exit the scanner to undergo the WL-SPT, a validated, non-invasive procedure for youth ages 8-16 to create visceral pain sensations which has been previously used by the research team to understand neural mechanisms of FAPD pain [1].

Participants will ingest water until they have achieved complete fullness eliciting discomfort (~5 minutes). Immediately following the WL-SPT, participants will rate their current pain and anxiety. Then, participants will re-enter the scanner and repeat a similar series of scans (~20 minutes) with current pain and anxiety ratings. At the completion of all scans, participants will rate their current pain and anxiety once more. Post-assessment measures will follow these same procedures.

266 2.5.1. Primary Outcomes (collected at pre and post assessments). Blood oxygenation level
267 dependent (BOLD) resting-state fMRI (rs-fMRI) will be used to assess functional connectivity
268 between the left and right amygdala and brain regions implicated in the FAPD pain experience

269 [1, 15-18] prior to and following WL-SPT, in those undergoing ADAPT versus waitlist.

270 *2.5.2. Secondary Outcomes (collected at pre and post assessments).* Similarly, the potential

271 regional cerebral blood flow (CBF) prior to and following WL-SPT, in the ADAPT group versus

waitlist will be assessed with the 3D PASL MRI perfusion technique.

273 2.5.3. Exploratory Outcomes (collected at pre and post assessments). We will explore if
changes in functional connectivity (BOLD) and regional CBF following ADAPT will correspond
to reductions in pain (intensity and unpleasantness) and anxiety ratings. We will also explore the
effect of pain on the connectivity of all 17 brain networks as defined by Yeo et al. [24].

Magnetic Resonance Imaging (MRI): MRI data will be acquired on a Siemens Prisma
3T scanner with a 64-channel head/neck coil. Image quality using this scanner has been certified
by an MRI physicist (DZ and YZ) based on both human brain and phantom scans. The following
three sequences will be used in this study:

- 281 (1) <u>3D T1-weighted Magnetization-Prepared-Rapid-Acquisition-of-Gradient-Echo (</u>3D
- MPRAGE) sequence (5 min 12 sec) will be used to visualize anatomical regions and 282 to isolate regions of interest for the analyses of functional connectivity and CBF. 283 Acquisition parameters: voxel size =  $1 \times 1 \times 1$  mm<sup>3</sup>, field of view (FOV) =  $256 \times 256$ 284  $mm^2$ , 208 sagittal slices, time of repetition (TR) = 2300 ms, time of echo (TE) = 2.98 285 ms, time of inversion (TI) = 900 ms, flip angle (FA) =  $9^{\circ}$ , and parallel imaging 286 acceleration factor = 2. Brain parcellation, regional and whole-brain volume 287 calculation will be performed using FreeSurfer [25]. The accuracy of the procedures 288 will be confirmed by visual inspection. 289
- 290 (2) <u>rs-fMRI (12 min 2 sec) will be used to assess functional connectivity</u>. In a dim-light 291 environment, a 12-minute rs-fMRI scan will be acquired while the subjects are asked 292 to relax and have their eyes closed [26]. An eye-closed condition will likely be easier 293 to maintain for our subjects [27, 28]. Acquisition parameters: Isotropic voxel size of 294  $2.5 \times 2.5 \times 2.5 \text{ mm}^3$ , 60 contiguous axial slices, FOV = 22 cm × 22 cm, TE = 30 ms, 295 TR = 1100 ms, FA = 63°, 4 dummy time points discarded, 650 time points, and

296	simultaneous multislice acceleration factor = 4. Data will be analyzed using AFNI
297	[29]. Slice-timing and motion corrections will be applied. Seed-based functional
298	connectivity to the left/right amygdala will be analyzed based on the correlation
299	between the mean time-course at the left/right amygdala and other voxels in the rest
300	of the brain. Similar seed-based connectivity analyses can be carried to other brain
301	regions.
302	In addition to examining functional connectivity to the amygdala, we will also
303	calculate the network connectivity of the 17 functional networks defined in the atlas
304	developed by Yeo et al. [24], which is based on rs-fMRI datasets from 1,000 healthy
305	young adults as part of our exploratory analysis. Since pain is a heterogenous
306	experience with multiple networks involved, we will explore these 17 networks
307	broadly and also anticipate specific patterns of change emerging for the default mode
308	network [1] defined in this atlas.
309	(3) <u>3D Pulse Arterial Spin Labeling (</u> 3D PASL) sequence at a perfusion mode of FAIR
310	QII (5 min 24 sec) will be used to measure regional CBF [30, 31]. Acquisition
311	parameters: 3D acquisition with FOV = $240 \times 240$ mm <sup>2</sup> , matrix size = $64 \times 64$ , 32
312	4.5-mm axial slices, $TR = 4000 \text{ ms}$ , $TE = 20.26 \text{ ms}$ , bolus duration = 800 ms,
313	inversion time = 2000 ms,10 control-label pairs of images acquired and averaged to
314	improve signal/noise ratio, and fat saturation. The relative CBF maps will be
315	generated based on the relatively difference of the control and label images.
316	
317	The 3D MPRAGE images will be collected at the beginning of the scan. To assess the
318	effect of WL-SPT on functional connectivity and CBF, the rs-fMRI and ASL images will

319	be collected before and after the WL-SPT (Fig 4). Participants are instructed not to
320	consume food or water within one hour prior to the MRI scan. Total MRI scanning time
321	is approximately 45 minutes per session to minimize participant burden.
322	Fig 4. MRI Procedure. The timing scheme of pain and anxiety ratings, MRI and WL-
323	SPT.
324	2.5.3. Exploratory Outcomes (collected at pre and post assessments)
325	Pain Intensity and Unpleasantness Visual Analog Scales (VAS) [32, 33]. Pain
326	intensity is associated with nociceptive processing and is a common measure of treatment
327	response [34]. Pain unpleasantness is related to affective network activity and is highly
328	responsive to meditation [35]. These will be collected using a physical sliding scale
329	during neuroimaging.
330	State Anxiety (VAS) [36]. 0-10 self-report of how anxious the child is feeling in the
331	present moment. This will be collected with a physical sliding scale during
332	neuroimaging.
333	2.5.4. Other Related Measures (collected at pre and post assessments unless otherwise specified)
334	Fullness Rating Scale [37]. Youth will be asked to indicate how full they felt after water
335	ingestion by selecting from images representing different levels of fullness, from empty
336	(coded 0) to full (coded 4). This will be collected in person during neuroimaging.
337	Edinburgh Handedness Inventory [38]. A validated measure that assesses the
338	dominance of a person's right or left hand in everyday activities. Given our pediatric
339	sample, one original item was removed (striking a match).

Menstruation Query. Female participants who have reached menarche will be asked if
they are currently menstruating and if so, how much pain is associated (using a visual
sliding scale). During screening, participants will be asked if they have achieved
menarche. If participants indicate that they have, we will query the date of their last
menstrual cycle.
Peterson Pubertal Developmental Scale (PDS) [39]. A valid and reliable pubertal status

346 assessed via clinician interview.

347 **Concomitant Medication Form**. Concomitant medication information (medication 348 name, reason for taking, unit, frequency, route, etc.) and therapies will be obtained via 349 chart review prior to the baseline visit. Study staff will confirm with caregivers that the 350 information is correct and up to date at the baseline and post assessment visits. Any 351 changes in medication from baseline to post assessment will be documented.

2.5.5. Participant Characteristics and Demographic Factors (collected at pre and post
 assessments unless otherwise indicated)

354 Child Pain History & Sociodemographic Factors. Demographic factors, school
 355 absences, pain duration, location, concomitant psychological treatments, and insurance
 356 type. Birth date, sex, gender, race, and ethnicity of participant will also be collected.

- **Primary Care Provider.** The name of participant's primary care provider and the name
- of their practice, along with contact information will be collected at the pre assessment.

359 2.5.6. Screening Measures (collected at screening, prior to study enrollment)

360	Rome IV FAPD Diagnosis Checklist [21] (medical provider report). FAPD criteria
361	based on the Rome IV criteria [21]. FAPD includes irritable bowel syndrome (IBS),
362	functional dyspepsia, abdominal migraine, and FAPD- not otherwise specified. To meet
363	the criteria for FAPD, a child must endorse continuous or episodic pain at least 4 times in
364	a month that does not exclusively occur during a physiological event (e.g., eating,
365	menses) for a period of 2 months or longer, and that cannot be fully explained by another
366	medical condition after appropriate evaluation. This questionnaire will allow us to group
367	our samples into specific diagnostic subtypes of FAPD.
368	Generalized Anxiety Disorders-7, GAD-7 [19]. A seven-item measure assessing for
369	generalized anxiety symptoms in the last two-weeks. The measure has a cut-off score for
370	moderate anxiety $\geq 10$ . This measure has been validated for use in pediatric populations
371	[40]. This measure is also collected at the post assessment.
372	Patient Health Questionnaire-9 [22]. A validated and reliable measure of depressive
373	symptoms in the past 2 weeks. Categories of severity are as follows: 0-4: Minimal
374	Depression, 5-9: Mild Depression, 10-14: Moderate Depression, 15-19: Moderately
375	Severe Depression, 20-27: Severe Depression. This measure is also collected at the post
376	assessment. Those endorsing thoughts of death on this measure will undergo a
377	comprehensive safety assessment to rule out active suicidal ideation. Youth will be
378	excluded from participating in the study (and referred for additional care) if they report
379	current active suicidal ideation or if their score is 22 or higher.
380	MRI Safety and Screening. Research staff will screen for MRI contraindications to
381	determine if participant can safely complete MRI protocol.

382	Claustrophobia Screening. Research staff will screen for signs of claustrophobia to
383	determine if the participant is claustrophobic. A brief interview to further assess for a fear
384	of enclosed spaces will be administered. This interview was adapted from a portion of the
385	Anxiety Disorder Interview Schedule-Child Report [41], a validated, semi structured
386	diagnostic interview to assess for the presence of child psychological disorders.
387	Responses on this module will help to determine eligibility for the study and will be used
388	in an attempt to reduce instances of unanticipated participant anxiety during the
389	neuroimaging scan. This process has been effective in our pilot neuroimaging research
390	[1] with this population as we did not lose a single participant due to scanner-related
391	anxiety.
392	2.5.7. Pain Related Measures (collected at pre and post assessments)
393	Visual Analog Scale (VAS) [32] for pain. Participants will report their average, highest,
393 394	<b>Visual Analog Scale (VAS)</b> [32] <b>for pain</b> . Participants will report their average, highest, and lowest pain levels in the past two weeks. If the electronic or physical VAS slider
393 394 395	<b>Visual Analog Scale (VAS)</b> [32] <b>for pain</b> . Participants will report their average, highest, and lowest pain levels in the past two weeks. If the electronic or physical VAS slider cannot be used (e.g. due technical difficulties), the numeric rating scale (NRS) will be
393 394 395 396	<b>Visual Analog Scale (VAS)</b> [32] <b>for pain</b> . Participants will report their average, highest, and lowest pain levels in the past two weeks. If the electronic or physical VAS slider cannot be used (e.g. due technical difficulties), the numeric rating scale (NRS) will be used. Parents will also provide an assessment of their child's pain in the past two weeks.
393 394 395 396 397	<ul> <li>Visual Analog Scale (VAS) [32] for pain. Participants will report their average, highest, and lowest pain levels in the past two weeks. If the electronic or physical VAS slider cannot be used (e.g. due technical difficulties), the numeric rating scale (NRS) will be used. Parents will also provide an assessment of their child's pain in the past two weeks.</li> <li>Other Pain Locations. Participants will be queried about other pain sources besides</li> </ul>
<ul> <li>393</li> <li>394</li> <li>395</li> <li>396</li> <li>397</li> <li>398</li> </ul>	<ul> <li>Visual Analog Scale (VAS) [32] for pain. Participants will report their average, highest, and lowest pain levels in the past two weeks. If the electronic or physical VAS slider cannot be used (e.g. due technical difficulties), the numeric rating scale (NRS) will be used. Parents will also provide an assessment of their child's pain in the past two weeks.</li> <li>Other Pain Locations. Participants will be queried about other pain sources besides abdominal pain.</li> </ul>
<ul> <li>393</li> <li>394</li> <li>395</li> <li>396</li> <li>397</li> <li>398</li> <li>399</li> </ul>	<ul> <li>Visual Analog Scale (VAS) [32] for pain. Participants will report their average, highest, and lowest pain levels in the past two weeks. If the electronic or physical VAS slider cannot be used (e.g. due technical difficulties), the numeric rating scale (NRS) will be used. Parents will also provide an assessment of their child's pain in the past two weeks.</li> <li>Other Pain Locations. Participants will be queried about other pain sources besides abdominal pain.</li> <li>2.5.8. Functional Disability Related Outcomes (collected at pre and post assessments)</li> </ul>
<ul> <li>393</li> <li>394</li> <li>395</li> <li>396</li> <li>397</li> <li>398</li> <li>399</li> <li>400</li> </ul>	<ul> <li>Visual Analog Scale (VAS) [32] for pain. Participants will report their average, highest, and lowest pain levels in the past two weeks. If the electronic or physical VAS slider cannot be used (e.g. due technical difficulties), the numeric rating scale (NRS) will be used. Parents will also provide an assessment of their child's pain in the past two weeks.</li> <li>Other Pain Locations. Participants will be queried about other pain sources besides abdominal pain.</li> <li>2.5.8. Functional Disability Related Outcomes (collected at pre and post assessments)</li> <li>Functional Disability Inventory (FDI) [42]. A 15-item measure of physical/daily</li> </ul>
<ul> <li>393</li> <li>394</li> <li>395</li> <li>396</li> <li>397</li> <li>398</li> <li>399</li> <li>400</li> <li>401</li> </ul>	<ul> <li>Visual Analog Scale (VAS) [32] for pain. Participants will report their average, highest, and lowest pain levels in the past two weeks. If the electronic or physical VAS slider cannot be used (e.g. due technical difficulties), the numeric rating scale (NRS) will be used. Parents will also provide an assessment of their child's pain in the past two weeks.</li> <li>Other Pain Locations. Participants will be queried about other pain sources besides abdominal pain.</li> <li>2.5.8. Functional Disability Related Outcomes (collected at pre and post assessments)</li> <li>Functional Disability Inventory (FDI) [42]. A 15-item measure of physical/daily function in last few days. This measure has been validated in pediatric chronic pain [43]</li> </ul>

#### 403 NIH PROMIS Pain Related Disability Pain Interference Scale[44]. A validated

- 404 measure of functional impairment due to pediatric pain in the past 7 days.
- 405 *2.5.9. Mental Health Related Measures (collected at pre and post assessments)*
- Screen for Child Anxiety Related Disorders, SCARED [45]. Child anxiety (reported
  by child and parent) in the past 3 months; ≥25 is indicative of clinical anxiety. This
  measure has been recommended for use by the American Academy of Pediatrics [46] and
  has been validated in pediatric chronic pain [45, 47, 48] and used in pediatric FAPD
  samples [5, 9].
- 411 **Child COVID-19 Related Distress**. A child-reported item assessing the child's distress 412 in relation to the COVID-19 pandemic on a sliding scale from 0-10, with anchors labeled 413 "no distress" and "extreme distress". This measure was added prior to launching the 414 study and following the COVID-19 pandemic.
- 415 COVID-19 Exposure and Family Impact Survey (CEFIS) [49]. A measure from the
  416 Center for Pediatric Traumatic Stress to capture the impact of the COVID-19 pandemic
- 417 on families and caregivers. This measure was added following the COVID-19 pandemic,
  418 which occurred prior to launching the study.
- 419 Self-Efficacy Pain Scale- Child Version [50]. A validated and reliable 7-item measure
  420 of child self-efficacy (reported by both child and parent) when in pain.
- Affective Reactivity Index (ARI)- Self- Report . A validated 7-item measure of child
   irritability in the last 7 days. Participants will complete this measure as self-report, and
   caregivers will provide their report of the child.

424	Pain Catastrophizing Scale for Children [51]. A validated 13-item measure of
425	maladaptive beliefs about pain and feelings experienced when in pain. Participants will
426	complete this measure as self-report, and caregivers will provide their report of the child.
427	Depression Anxiety Stress Scales [52]. A validated and reliable measure with 21 items
428	completed by the caregiver of assessing for self-reported caregiver depression, anxiety,
429	and tension/stress.
430	Adverse Childhood Experiences (ACEs) [53]. A valid, 9-item measure used by the
431	National Survey of Children's Health that assesses for adverse events occurring in
432	childhood before the age of 18.
433	2.5.10. Concomitant Care.
434	Any concomitant interventions (i.e., medical, and psychological) experienced by the
435	participants (either allowed (e.g., pharmacological treatments for FAPD) or prohibited
436	(psychological therapy for anxiety or pain), see section 2.2 Eligibility Criteria) will also be
437	recorded at baseline and post assessments. Participants will provide the reason and duration of
438	concomitant interventions at the baseline and post assessment visits.
439	2.5.10. Adverse Event Queries.
440	Participants will be queried about any experienced adverse events during their second
441	session of ADAPT (if randomized to ADAPT treatment group). This form will also be
442	administered at post assessment. For those randomized to waitlist, they will complete this form
443	at post assessment, and then at ADAPT sessions 2 and 6 (if they opt to complete ADAPT).

444 Adverse Event Query Form. A form to be completed via clinician or research
 445 coordinator interview assessing for adverse events experienced by participants.

446 *2.6. Intervention* 

447 2.6.1. The Aim to Decrease Anxiety and Pain Treatment (ADAPT).

448 ADAPT is a psychological intervention that, in the current investigation, integrates 449 mindfulness meditation with cognitive behavioral therapy approaches for managing pain and anxiety to improve patient outcomes (see Table 1). ADAPT was originally developed from a 450 451 CBT protocol for pain management [12] and from the "Cool Kids" program for anxiety [11]. The 452 current iteration integrates mindfulness meditation strategies from an established protocol [13]. ADAPT is primarily a child-focused, individual therapy with some caregiver involvement. The 453 454 duration of ADAPT is 6 six weeks, although up to eight weeks will be permitted to account for scheduling conflicts and participant illness. In the current study, there will be two live 455 videoconference (Zoom) sessions with an interventionist (60 minutes) once per week for the first 456 457 two weeks, followed by 4 weeks of self-paced web modules (30 minutes per week) in conjunction with interventionist support (15-30 minutes per week). Prior to the study launch (as 458 a result of the COVID-19 pandemic), ADAPT was revised to be delivered fully remotely (e.g., 459 live, in-person sessions to be delivered via videoconferencing). In the event of technical 460 difficulties, live sessions can also be completed over phone calls. Preliminary testing has shown 461 462 that ADAPT is feasible and successfully reduces pain-related disability and anxiety over time [9, 14]. The interaction with the interventionist has been shown to be a key component engaging 463 youth in the program [54], and ADAPT has shown to be associated with improvements in 464 465 caregiver anxiety [55]. All participants will receive or be offered ADAPT, either immediately

#### 466 following baseline assessment and randomization, or after completing the post assessment if

Attendee(s)	Format	Content	
Participant, caregiver	Live via zoom	Introduction	
		Gate control theory of pain	
		Anxiety education*	
		Deep/mindful breathing	
		Guided Imagery	
Participant (with	Live via zoom	Progressive muscle relaxation	
caregiver review)		Calming statements	
		Activity Pacing	
Participant, caregiver	Web-based	Please activity scheduling	
	with Zoom	Problem solving	
Participant, caregiver	Web-based	Thinking like a detective*	
	with Zoom	Identifying and challenging automatic	
		thoughts	
Participant, caregiver	Web-based	Fighting fears by facing fears*	
	with Zoom	Building social skills: assertiveness*	
Participant, caregiver	Web-based	Maintenance planning	
	with Zoom		
	Attendee(s)         Participant, caregiver         Participant (with         caregiver review)         Participant, caregiver         Participant, caregiver         Participant, caregiver         Participant, caregiver	Attendee(s)FormatParticipant, caregiverLive via zoomParticipant (with caregiver review)Live via zoomParticipant, caregiverWeb-based with Zoom	

#### Table 1. ADAPT Protocol

467 participants are randomized to waitlist.

Note. Live sessions occur via HIPPA-compliant Zoom videoconferencing (1 hour). Web-based
sessions with zoom are self-paced modules (approximately 30 minutes) and therapist support
(approximately 15-30 minutes). All participants are permitted to continue their medical care as
usual throughout the duration of the study. \*Drawn from anxiety-specific treatment protocol,
"Cool Kids" [11]. The remaining content is adapted from a pain coping skills program [12] or a
mindfulness meditation protocol [13].

#### 474 *2.6.2 Treatment integrity*

All sessions will be video recorded (with patient permission) and stored. Treatment integrity will be assessed using video recordings of videoconference sessions by independent evaluators (e.g., doctoral students or medical trainees). Integrity scores (0–100%) used in prior research [12, 14] will be obtained. Items assessed included delivery of session-specific skills and assessment of participant comprehension. There will also be regular supervision of the interventionist with a licensed psychology to review protocol and insure treatment fidelity.

#### 481 2.6.3 Waitlist group

Participants in the waitlist arm will follow their gastroenterologists' recommendations for
FAPD management. Waitlist participants will not be permitted to receive psychological care for
pain or anxiety outside of the study during their participation in order to minimize possible
similar treatment effect on waitlist control group, and will be offered ADAPT following their
post assessment as a courtesy.

#### 487 2.7. Data Management and Monitoring

488 An external data monitoring committee comprising of 3 external MSU faculty with 489 specialties in bio-behavioral statistics, global neuropsychiatry, and neuroscience will meet

quarterly to assess study progress. The NCCIH will provide oversight via yearly study site visitsthrough Westat.

492 To ensure confidentiality, identification numbers will be used in lieu of names and data 493 will be kept in locked files in the PI's research location or on a secure computer that is designated specifically for the purposes of this project. All data (except for MRI data) will be 494 495 saved into REDCap, a password-protected database. To assure the accuracy of data entry, data will be verified in real-time by study staff via database-incorporated data entry checks. Data 496 output will be stored on a network devoted solely to the research activities associated with 497 MSU's Biomedical Research Informatics Core (BRIC). Electronic data stored on MSU's 498 network is backed up nightly by BRIC. Only the PI and designated members of her team will 499 have access to the final trial dataset. We expect to publish the results and share them on the 500 ClinicalTrials.gov database. 501

The High-Performance Computing Center (HPCC) will be used for checking, storing, and analyzing MRI data. The HPCC is maintained by MSU's Institute for Cyber-Enabled Research (ICER). The MRI data will also be stored on a secure server, backed up nightly, and will only be accessible to study staff.

While all efforts will be made to minimize missing data through the use of electronic data capture and real-time adherence data collection, missing data is still inevitable in RCTs. Thus, we will employ several strategies to handle missing data with specific attention on how to handle missing not-at-random data. Specifically, missing data will be handled via ML estimation with auxiliary correlate inclusion [56, 57]. Missing not at random will be addressed with mixture MNAR methods [58-60].

#### 512 2.8 Statistical Analysis Plan

513	Primary and secondary outcome measures are obtained from neuroimaging data. The
514	brain regions selected have been shown in prior literature to be related to chronic pain [1, 61] and
515	respond to psychological interventions for the management of chronic pain conditions [62].
516	The 3D T1-weighted MPRAGE images will be segmented via FreeSurfer "recon-all"
517	[25]. The segmentation will be used in rs-fMRI functional connectivity and CBF analyses.
518	For rs-fMRI data analysis, image pre-processing and data analysis will be accomplished
519	by Analysis of Functional Neuroimages (AFNI) [63] and FreeSurfer [25] softwares. Signal time
520	course spikes will be detected and removed. Data points with excessive motion will be identified
521	(normalized motion derivative > $0.5$ or vox outliers > $10\%$ ) and modeled as regressors in
522	subsequent processing. Acquisition timing differences across slice locations will be corrected.
523	Rigid-body motion correction will be applied in three translational and three rotational
524	directions. Translational and rotational estimates, as well as their derivatives, will be modeled as
525	regressors for the subsequent noise regression step. For each subject, spatial blurring with a full-
526	width half-maximum of 4mm will be used to reduce random noise. CSF and white matter mean
527	signals will be modeled as nuisance variables. A band-pass filter (0.009 Hz-0.08 Hz) will be
528	applied. For the time course at each voxel location, temporal noise discussed above will be
529	removed via "3dDeconvolve" feature in AFNI [63].
530	Functional Connectivity Analysis: Each functional connectivity map will be warped to
531	the standard MNI152 space via AFNI. Correlation coefficients for each subject will be
532	transformed using Fisher's Z. In the overall group analysis on the effect of WL-SPT, paired t-

tests between the pre and post WL-SPT functional connectivity maps will be conducted.

534 ANOVAs will be conducted on the functional connectivity differences between the ADAPT

completers and those in the waitlist condition. Statistically significant regions will be identified
based on p<0.05 after multiple comparison correction, which will be estimated according to</li>
Monte Carlo simulations in AFNI [63]. Changes between the amygdala and other network
regions (e.g., thalamus) that are implicated in pain processing are expected following ADAPT
versus waitlist (both following WL-SPT, and while at rest).

540 Regional CBF analyses: The relative CBF maps will be generated for each PASL scan.
541 We will use a whole-brain search to identify areas associated with connectivity with the
542 amygdala. The CBF maps will be aligned to the T1 MPRAGE. The mean CBF values on the
543 regions segmented by FreeSurfer (Fischl, 2012) will be calculated. The percentage change at
544 each region due to WL-SPT will be calculated. ANOVAs testing the percentage change of CBF
545 at the brain regions will be completed to compare the ADAPT completers to those in the waitlist
546 condition.

547 Pain-related brain CBF is expected to diminish for those that complete ADAPT compared
548 to the waitlist condition (Aim 2) following the WL-SPT and while at rest.

Exploratory Analyses: Neural mechanisms associated with a positive treatment
response (decreased pain intensity, unpleasantness, and state anxiety (after the WL-SPT and
while at rest) after ADAPT will be identified. Normalization of abnormal connectivity patterns
are predicted to categorize changes in participant-reported pain and anxiety. Specifically,
decreases in brain CBF and reductions in functional connectivity will be examined in relation to
improvements in pain and anxiety post treatment using multiple (linear) regression.

555 Given that other factors such as pubertal status and subjective pain levels could influence 556 the outcome, these factors will be included in the analysis as control covariates. Each

557	participant's exact age will be recorded at assessment allowing personnel to control for age as an
558	additional covariate should the need become apparent during preliminary analyses.

Network-based exploratory connectivity analysis will also be conducted. The cortical nodes of the 17 networks identified by Yeo and colleagues (2011) will be identified via Freesurfer segmentation (Fischl, 2012). Correlation between each pair of nodes in each network will be calculated in MATLAB [64]. The connectivity within each network is the average of the correlations of all pairs of nodes within a network. In assessing whole-brain connectivity, the global average of the absolute r values between all nodes will be taken (to account for networks known to be anticorrelated).

All correlation coefficients of each subject will be transformed using Fisher's Z using SPSS (IBM SPSS Statistics for Windows, Version 26.0). In the overall group analysis on the effect of WL-SPT, paired t-tests between the pre and post WL-SPT functional connectivity of each network and global connectivity will be conducted. ANOVAs will be conducted to investigate functional connectivity differences between the ADAPT completers and those in the waitlist condition.

572 2.8.1. Sample size and randomization specifications

We used the following tool (http://neuropowertools.org/neuropower/neuropowerinput/) to conduct sample size calculations for the rs-fMRI portion of the study. Power calculations were based on prior studies by research members on functional connectivity data 1) pre and post psychological therapy for pediatric pain (migraine) [65], and 2) comparing individuals with pediatric pain (migraine) to healthy controls [66] .

For within group changes, we relied on the pre/post data following a psychological therapy for pediatric pain (migraine) [65]. A total sample size of 34 is required for power of .8 and p < 0.05 to observe at least moderate (e.g. mean effect size difference of 0.4 or greater) effects. For between group changes, we utilized data comparing youth with chronic pain (migraine) to healthy controls [66]. Based on these data, a total of 35 subjects are required for power of .8 and p < 0.05.

584 2.9 Interim analyses and stopping rules

There are no planned interim analyses. Dr. Barber Garcia will assess adherence and retention. If the treatment is deemed to be ineffective, unsafe, futile, or if there is evidence of poor study performance (e.g., slow accrual, high losses-to-follow-up, and poor quality control), a safety review may be warranted. This action would occur in consultation with the study mentors (Zhu, Arnetz), the IMC, and NCCIH.

590

#### Discussion

FAPD are a set of common and chronic abdominal pain conditions [20, 21, 67] generally 591 categorized by hyperconnectivity between the amygdala and other regions of the brain 592 implicated in cognition and pain- processing [1, 61, 68, 69]. Further, FAPD are associated with 593 significant psychosocial impairment and may persist for a subset of youth [70, 71]. Pain-related 594 outcomes of FAPD are worse in the presence of comorbid anxiety [5, 72]. Further, anxiety, in 595 combination with clinically elevated levels of pain and pain-related disability, are associated 596 with persistent functional impairment [8]. Anxiety also diminishes impact of pain-focused CBT 597 [9], which is among the most widely researched approach to care for pediatric chronic pain 598 conditions [73]. Fortunately, a coping skills program called the Aim to Decrease Anxiety and 599 600 Pain Treatment (ADAPT) has been developed [10] that addresses comorbid anxiety and chronic

pain symptoms for youth with FAPD. The program consists of a blend of CBT strategies and 601 was infused with mindfulness meditation to be delivered by a trained interventionist weekly for a 602 period of six weeks [10, 14]. ADAPT has shown to be superior to improving pain-related 603 disability and anxiety as compared to standard care in a randomized clinical trial [14]. However, 604 the potential neural mechanisms underlying the effect of this treatment are unknown. Once such 605 606 factors are investigated through our neuromechanistic trial, we will have an enhanced understanding of mechanisms underlying treatment response to psychological interventions 607 addressing pain and comorbid anxiety. 608

609 Our trial utilizes a validated visceral symptom provocation task, the water loading symptom provocation task (WL-SPT) [37]. We have intentionally used this task during 610 neuroimaging the brains of youth with FAPD [1], who otherwise may or may not be 611 experiencing an active pain flare at the time of imaging. The WL-SPT is known to induce 612 sensations including pain intensity and pain unpleasantness similar to, but less severe than, an 613 active pain flare [37]. Therefore, in our current neuromechanistic trial, we will compare youth 614 functional connectivity between the amygdala and other regions of the brain after ADAPT versus 615 waitlist during after the WL-SPT, in addition to rest. To enhance the rigor of the results, visual 616 617 analog measures of pain severity/unpleasantness [32, 33] and anxiety [36] will be obtained throughout the scanning. Such a research design employing a validated visceral symptom 618 619 provocation task has the potential to advance the literature.

We expect minimal risk and potential benefits to participants and their families following receipt of the ADAPT program, which is an evidence-based program to improve pain-related disability and anxiety in youth with FAPD [14]. Limitations of the current study design include lack of active treatment comparator and a relatively modest sample size. We also recognize

functional connectivity is based on surrogates of neural activity (i.e., changes in blood flow in
response to neural activity); thus, findings should be interpreted within that lens. Future planned
research includes dissemination and implementation trials, examining sustainability of treatment
effects and associated neural mechanisms, and investigating neural mechanisms underlying
components of treatment response, similar to work currently underway in pediatric migraine
[65].

Given that FAPD are common [2] and costly [74] conditions associated with changes in 630 631 neural processing [1], and effective programs such as ADAPT are available [14], it is important 632 to understanding neural mechanisms of treatment response. This is particularly true in the adolescent population as FAPD [5, 8] and anxiety [75] increases and can become more severe as 633 children age and transition to adolescence. This is a period marked by pubertal and 634 developmental changes that may alter changes in neural functioning associated with pain 635 processing [76]. Therefore, additional investigation of the impact of pubertal status on pain 636 637 processing following effective treatments will be important in future research. Though this work is specific to FAPD, findings may be a guide to enhance the understanding of treatment response 638 of other pediatric chronic pain conditions (which are also generally categorized by enhanced 639 640 functional connectivity between the amygdala and other regions associated with pain) [77, 78]. This is critically important as chronic pain conditions are the most common childhood chronic 641 642 illnesses and most expensive health problem facing children in the US [79].

#### 643 Conclusion

In conclusion, this is the first neuromechanistic RCT of a tailored psychological treatment to
target pain and anxiety in youth with FAPD. Results aim to improve understanding of
mechanisms underlying response to psychological treatments for FAPD.

647	Acknowledgements				
648	We thank the gastroenterology team at Helen DeVos Children's Hospital including Drs. Vanessa				
649	Cardenas-Soto, Peter Freswick, Deborah Cloney, Sarah Henkel, Amie Hinshaw, nurse				
650	practitioner Ashley Verhey, and social workers Mackenzie Mullins and Jamie Bart for				
651	supporting the recruitment efforts and execution of the study. We thank Drs. Amy Pugh,				
652	Alexander Redman, Christina Varghese, and Leo Fawaz for providing on-call services. We thank				
653	Mallet Reid and Sukhesh Sudan for their assistance with randomization. We thank Emme				
654	Bourassa, Kara Nearanz, and Caitlin Wilterink for their support as Corewell Health research				
655	assistants. We thank Elise Cheney-Makens for her support with recruitment. We thank Robert				
656	Jones, Stacy Clegg, Becky Ruiter, Carrie Popilek, Michele Harvey, Steven Zomberg, and Crista				
657	Bradley for their support as MRI technologists on the project.				
658					
659					
660					
000					
661					
662					
663					
664					
004					
665					
666					
667					

#### 668 **References**

Cunningham NR, Nahman-Averbuch H, Lee GR, King CD, Coghill RC. Amygdalar
functional connectivity during resting and evoked pain in youth with functional abdominal pain
disorders. J Pain. 2022;163(10):2031-43.

King S, Chambers CT, Huguet A, MacNevin RC, McGrath PJ, Parker L, et al. The
epidemiology of chronic pain in children and adolescents revisited: a systematic review. J Pain.
2011;152(12):2729-38.

Walker LS, Sherman AL, Bruehl S, Garber J, Smith CA. Functional abdominal pain patient
subtypes in childhood predict functional gastrointestinal disorders with chronic pain and
psychiatric comorbidities in adolescence and adulthood. J Pain. 2012;153(9):1798-806.

4. Størdal K, Nygaard EA, Bentsen BS. Recurrent abdominal pain: a five-year follow-up
study. Acta Paediatr. 2005;94(2):234-6.

5. Cunningham NR, Cohen MB, Farrell MK, Mezoff AG, Lynch-Jordan A, Kashikar-Zuck
S. Concordant parent-child reports of anxiety predict impairment in youth with functional
abdominal pain. J Pediatr Gastroenterol Nutr. 2014;60(3):312-7.

683 6. Dorn LD, Campo JC, Thato S, Dahl RE, Lewin D, Chandra R, et al. Psychological 684 comorbidity and stress reactivity in children and adolescents with recurrent abdominal pain and 685 anxiety disorders. J Am Acad Child Adolesc Psychiatry. 2003;42(1):66-75.

Dufton LM, Dunn MJ, Compas BE. Anxiety and somatic complaints in children with
 recurrent abdominal pain and anxiety disorders. J Pediatr Psychol. 2009;34(2):176-86.

688 8. Cunningham NR, Jagpal A, Peugh J, Cohen MB, Farrell MK, Mezoff AG, et al. Using a
689 simple risk categorization to predict outcomes in pediatric functional abdominal pain at 6 months
690 J Pediatr Gastroenterol Nutr. 2017;64(5):685-90.

691 9. Cunningham NR, Jagpal A, Tran ST, Kashikar-Zuck S, Goldschneider KR, Coghill RC, et
692 al. Anxiety Adversely Impacts Response to Cognitive Behavioral Therapy in Children with
693 Chronic Pain. J Pediatr. 2016;171:227-33.

Cunningham NR, Nelson S, Jagpal A, Moorman E, Farrell M, Pentiuk S, et al.
Development of the Aim to Decrease Anxiety and Pain Treatment for Pediatric Functional
Abdominal Pain Disorders. J Pediatr Gastroenterol Nutr. 2018;66(1):16-20.

Lyneham HJ, Abbott MJ, Wignall A, Rapee RA. The Cool Kids Anxiety TreatmentProgram. 2003.

Kashikar-Zuck S, Ting TV, Arnold LM, Bean J, Powers SW, Graham TB, et al. Cognitive
behavioral therapy for the treatment of juvenile fibromyalgia: a multisite, single-blind,
randomized, controlled clinical trial. Arthritis Rheum. 2012;64(1):297-305.

13. Broderick P. Learning to breathe. Oakland, CA: New Harbinger Publications; 2013.

14. Cunningham NR, Kalomiris A, Peugh J, Farrell M, Pentiuk S, Mallon D, et al. Cognitive
Behavior Therapy Tailored to Anxiety Symptoms Improves Pediatric Functional Abdominal Pain
Outcomes: A Randomized Clinical Trial. J Pediatr. 2021;230:62-70.e3.

Raichle ME, MacLeod AM, Snyder AZ, Powers WJ, Gusnard DA, Shulman GL. A default
 mode of brain function. Proceedings of the national academy of sciences. 2001;98(2):676-82.

Baliki MN, Chialvo DR, Geha PY, Levy RM, Harden RN, Parrish TB, et al. Chronic pain
and the emotional brain: specific brain activity associated with spontaneous fluctuations of
intensity of chronic back pain. J Neurosci. 2006;26(47):12165-73.

17. Baliki MN, Geha PY, Apkarian AV, Chialvo DR. Beyond feeling: chronic pain hurts the
brain, disrupting the default-mode network dynamics. J Neurosci. 2008;28(6):1398-403.

18. Cunningham NR, Kashikar-Zuck S, Coghill RC. Brain mechanisms impacted by
psychological therapies for pain: identifying targets for optimization of treatment effects. PAIN
Reports. 2019;4(4):e767.

- 715 Reports: 2017,4(4).0707.
  716 19. Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized
  717 ansists disorder the CAD 7. And Intern Med 200(110((10))1002.7)
- 717 anxiety disorder: the GAD-7. Arch Intern Med. 2006;166(10):1092-7.
- Walker LS, Lipani TA, Greene JW, Caines K, Stutts J, Polk DB, et al. Recurrent abdominal
  pain: symptom subtypes based on the Rome II Criteria for pediatric functional gastrointestinal
- disorders. J Pediatr Gastroenterol Nutr. 2004;38(2):187-91.
- Koppen IJ, Nurko S, Saps M, Di Lorenzo C, Benninga MA. The pediatric Rome IV criteria:
  what's new? Expert Rev Gastroenterol Hepatol. 2017;11(3):193-201.
- Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity
  measure. J Gen Intern Med. 2001;16(9):606-13.
- Kroenke K, Spitzer RL, Williams JB, Löwe B. An ultra-brief screening scale for anxiety
  and depression: the PHQ-4. Psychosomatics. 2009;50(6):613-21.
- Yeo BT, Krienen FM, Sepulcre J, Sabuncu MR, Lashkari D, Hollinshead M, et al. The
  organization of the human cerebral cortex estimated by intrinsic functional connectivity. J
  Neurophysiol. 2011;106(3):1125-65.
- 730 25. Fischl B. FreeSurfer. Neuroimage. 2012;62(2):774-81.
- Birn RM, Molloy EK, Patriat R, Parker T, Meier TB, Kirk GR, et al. The effect of scan
  length on the reliability of resting-state fMRI connectivity estimates. Neuroimage. 2013;83:5508.
- Fernandez Z, Scheel N, Baker JH, Zhu DC. Functional connectivity of cortical resting-state
   networks is differentially affected by rest conditions. Brain Res. 2022;1796:148081.
- Chang SE, Zhu DC. Neural network connectivity differences in children who stutter. Brain.
  2013;136(Pt 12):3709-26.
- 738 29. Cox RW. AFNI: what a long strange trip it's been. Neuroimage. 2012;62(2):743-7.
- 30. Kim SG. Quantification of relative cerebral blood flow change by flow-sensitive
  alternating inversion recovery (FAIR) technique: application to functional mapping. Magn Reson
  Med. 1995;34(3):293-301.
- 31. Wong EC, Buxton RB, Frank LR. Quantitative imaging of perfusion using a single
  subtraction (QUIPSS and QUIPSS II). Magn Reson Med. 1998;39(5):702-8.
- McGrath PJ, Walco GA, Turk DC, Dworkin RH, Brown MT, Davidson K, et al. Core
  outcome domains and measures for pediatric acute and chronic/recurrent pain clinical trials:
  PedIMMPACT recommendations. J Pain. 2008;9(9):771-83.
- 747 33. Price DD, Bush FM, Long S, Harkins SW. A comparison of pain measurement
  748 characteristics of mechanical visual analogue and simple numerical rating scales. J Pain.
  749 1994;56(2):217-26.
- 750 34. Palermo TM, Eccleston C, Lewandowski AS, Williams ACdC, Morley S. Randomized
  751 controlled trials of psychological therapies for management of chronic pain in children and
  752 adolescents: an updated meta-analytic review. J Pain. 2010;148(3):387-97.
- Zeidan F, Martucci KT, Kraft RA, Gordon NS, McHaffie JG, Coghill RC. Brain
  mechanisms supporting the modulation of pain by mindfulness meditation. J Neurosci.
  2011;31(14):5540-8.
- 756 36. Kindler CH, Harms C, Amsler F, Ihde-Scholl T, Scheidegger D. The visual analog scale
- allows effective measurement of preoperative anxiety and detection of patients' anestheticconcerns. Anesth Analg. 2000;90(3):706-12.

37. Walker LS, Williams SE, Smith CA, Garber J, Van Slyke DA, Lipani T, et al. Validation 759 of a symptom provocation test for laboratory studies of abdominal pain and discomfort in children 760 and adolescents. J Pediatr Psychol. 2006;31(7):703-13. 761

762 38. Oldfield RC. The assessment and analysis of handedness: the Edinburgh inventory. Neuropsychologia. 1971;9(1):97-113. 763

Petersen AC, Crockett L, Richards M, Boxer A. A self-report measure of pubertal status: 764 39. Reliability, validity, and initial norms. J Youth Adolesc. 1988;17(2):117-33. 765

Mossman SA, Luft MJ, Schroeder HK, Varney ST, Fleck DE, Barzman DH, et al. The 766 40. Generalized Anxiety Disorder 7-item scale in adolescents with generalized anxiety disorder: 767 Signal detection and validation. Ann Clin Psychiatry. 2017;29(4):227-34a. 768

Albano A, Silverman W. The Anxiety Disorders Interview Schedule for Children for DSM-769 41. 770 IV: Clinician manual (child and parent versions). San Antonio, TX: Psychological Corporation. 1996;183:649-56. 771

Walker LS, Greene JW. The functional disability inventory: measuring a neglected 772 42. dimension of child health status. J Pediatr Psychol. 1991;16(1):39-58. 773

Kashikar-Zuck S, Flowers S, Claar R, Guite J, Logan D, Lynch-Jordan A, et al. Clinical 774 43. 775 utility and validity of the Functional Disability Inventory among a multicenter sample of youth with chronic pain. J Pain. 2011;152(7):1600-7. 776

Varni JW, Stucky BD, Thissen D, DeWitt EM, Irwin DE, Lai J-S, et al. PROMIS Pediatric 777 44. 778 Pain Interference Scale: an item response theory analysis of the pediatric pain item bank. J Pain. 779 2010;11(11):1109-19.

Birmaher B, Khetarpal S, Brent D, Cully M, Balach L, Kaufman J, et al. The Screen for 780 45. Child Anxiety Related Emotional Disorders (SCARED): Scale construction and psychometric 781 characteristics. J Am Acad Child Adolesc Psychiatry. 1997;36(4):545-53. 782

Mental Health Screening and Assessment Tools for Primary Care. 2010. In: Addressing 783 46. 784 Mental Health Concerns in Primary Care [Internet]. Am Acad Pediatr

Birmaher B, Brent D, Chiappetta L, Bridge J, Monga S, Baugher M. Psychometric 785 47. properties of the Screen for Anxiety Related Emotional Disorders (SCARED): A replication study. 786 J Am Acad Child Adolesc Psychiatry. 1999;38(10):1230-6. 787

Mano KEJ, Evans JR, Tran ST, Khan KA, Weisman SJ, Hainsworth KR. The psychometric 788 48. properties of the Screen for Child Anxiety Related Emotional Disorders in pediatric chronic pain. 789 J Pediatr Psychol. 2012;37(9):999-1011. 790

COVID-19 Exposure and Family Impact Survey (CEFIS). 2020. 791 49.

50. Bursch B, Tsao JC, Meldrum M, Zeltzer LK. Preliminary validation of a self-efficacy scale 792 for child functioning despite chronic pain (child and parent versions). J Pain. 2006;125(1):35-42. 793

Crombez G, Bijttebier P, Eccleston C, Mascagni T, Mertens G, Goubert L, et al. The child 794 51. 795 version of the pain catastrophizing scale (PCS-C): a preliminary validation. J Pain. 2003;104(3):639-46. 796

797 52. Henry JD, Crawford JR. The short-form version of the Depression Anxiety Stress Scales (DASS-21): Construct validity and normative data in a large non-clinical sample. Br J Clin 798 Psychol. 2005;44(2):227-39. 799

800 53. Bethell CD, Carle A, Hudziak J, Gombojav N, Powers K, Wade R, et al. Methods to assess adverse childhood experiences of children and families: toward approaches to promote child well-801

being in policy and practice. Acad Pediatr. 2017;17(7):S51-S69. 802

54. Miller AK, Ely SL, Barber Garcia BN, Richardson P, Cunningham NR. Engagement
during a Mixed In-Person and Remotely Delivered Psychological Intervention for Youth with
Functional Abdominal Pain Disorders and Anxiety. Children (Basel). 2021;8(9).

55. Kalomiris AE, Ely SL, Love SC, Mara CA, Cunningham NR. Child-Focused Cognitive
Behavioral Therapy for Pediatric Abdominal Pain Disorders Reduces Caregiver Anxiety in
Randomized Clinical Trial. J Pain. 2022;23(5):810-21.

- Solution Structural Equation
  Struct Equ Modeling. 2003;10(1):80-100.
- 811 57. Enders C. Applied Missing Data Analysis. The Guilford Press2010.
- 58. Gottfredson NC, Bauer DJ, Baldwin SA. Modeling Change in the Presence of NonRandomly Missing Data: Evaluating A Shared Parameter Mixture Model. Struct Equ Modeling.
  2014;21(2):196-209.
- 815 59. Muthén B, Asparouhov T, Hunter AM, Leuchter AF. Growth modeling with nonignorable
  816 dropout: alternative analyses of the STAR\*D antidepressant trial. Psychol Methods.
  817 2011;16(1):17-33.
- 818 60. Sterba SK, Gottfredson NC. Diagnosing global case influence on MAR versus MNAR
  819 model comparisons. Struct Equ Modeling. 2015;22(2):294-307.
- 820 61. Simons LE, Moulton EA, Linnman C, Carpino E, Becerra L, Borsook D. The human
  821 amygdala and pain: evidence from neuroimaging. Hum Brain Mapp. 2014;35(2):527-38.
- 822 62. Simons LE, Pielech M, Erpelding N, Linnman C, Moulton E, Sava S, et al. The responsive
  823 amygdala: treatment-induced alterations in functional connectivity in pediatric complex regional
  824 pain syndrome. J Pain. 2014;155(9):1727-42.
- 63. Cox RW. AFNI: software for analysis and visualization of functional magnetic resonance
  neuroimages. Comput Biomed Res. 1996;29(3):162-73.
- 64. MATLAB 9.13.0 (R2022b) ed. Natick, Massachusetts: The MathWorks Inc.; 2022.
- 828 65. Nahman-Averbuch H, Schneider VJ, 2nd, Chamberlin LA, Kroon Van Diest AM, Peugh
- JL, Lee GR, et al. Alterations in Brain Function After Cognitive Behavioral Therapy for Migraine
   in Children and Adolescents. Headache. 2020;60(6):1165-82.
- 831 66. Nahman-Averbuch H, Leon E, Hunter BM, Ding L, Hershey AD, Powers SW, et al.
  832 Increased pain sensitivity but normal pain modulation in adolescents with migraine. J Pain.
  833 2019;160(5):1019-28.
- 834 67. Walker LS, Lipani TA, Greene JW, Caines K, Stutts J, Polk DB, et al. Recurrent abdominal
  835 pain: symptom subtypes based on the Rome II criteria for pediatric functional gastrointestinal
- disorders. J Pediatr Gastroenterol Nutr. 2004;38(2):187-91.
- 68. Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain regions
  activated during rectal distension in irritable bowel syndrome. J Gastroenterol. 2011;140(1):91100.
- 69. Liu X, Silverman A, Kern M, Ward BD, Li SJ, Shaker R, et al. Excessive coupling of the
  salience network with intrinsic neurocognitive brain networks during rectal distension in
  adolescents with irritable bowel syndrome: a preliminary report. Neurogastroenterol Motil.
  2016;28(1):43-53.
- Walker LS, Guite JW, Duke M, Barnard JA, Greene JW. Recurrent abdominal pain: A
  potential precursor of irritable bowel syndrome in adolescents and young adults. J Pediatr.
  1998;132(6):1010-5.

Ramchandani PG, Fazel M, Stein A, Wiles N, Hotopf M. The impact of recurrent
abdominal pain: predictors of outcome in a large population cohort. Acta Paediatr.
2007;96(5):697-701.

Stanford EA, Chambers CT, Biesanz JC, Chen E. The frequency, trajectories and predictors
of adolescent recurrent pain: A population-based approach. J Pain. 2008;138(1):11-21.

- Fisher E, Villanueva G, Henschke N, Nevitt SJ, Zempsky W, Probyn K, et al. Efficacy and
  safety of pharmacological, physical, and psychological interventions for the management of
  chronic pain in children: a WHO systematic review and meta-analysis. J Pain. 2022;163(1):e1e19.
- 74. Dhroove G, Chogle A, Saps M. A Million-dollar Work-up for Abdominal Pain: Is It Worth
  It? J Pediatr Gastroenterol Nutr. 2010;51(5):579-83 10.1097/MPG.0b013e3181de0639.
- APA. Diagnostic and statistical manual of mental disorders (5th ed). Arlington, VA: Am
  Psychiatr Publ; 2013.
- Nahman-Averbuch H, Li R, Boerner KE, Lewis C, Garwood S, Palermo TM, et al.
  Alterations in pain during adolescence and puberty. Trends Neurosci. 2023;46(4):307-17.
- 862 77. Simons LE, Moulton EA, Linnman C, Carpino E, Becerra L, Borsook D. The human
  863 amygdala and pain: evidence from neuroimaging. Hum Brain Mapp. 2014;35(2):527-38.
- 864 78. Erpelding N, Simons L, Lebel A, Serrano P, Pielech M, Prabhu S, et al. Rapid treatment865 induced brain changes in pediatric CRPS. Brain Struct Funct. 2016;221(2):1095-111.
- 866 79. Groenewald CB, Essner BS, Wright D, Fesinmeyer MD, Palermo TM. The Economic
- Costs of Chronic Pain Among a Cohort of Treatment-Seeking Adolescents in the United States. J
  Pain. 2014;15(9):925-33.

869

	STUDY PERIOD				
	Enrollment	Baseline	Randomization	Post Assessment	
TIMEPOINT	-t1	<b>t</b> 1		t2	
mERNBROIL MENTEN 1024.02 (which was not certified by peer review) is the It is made a	08.24302498; this version posted Februa author/funder, who has granted medRxiv a ailable under a CC-BY 4.0 International lic	y 9, 2024. The copyright holder for thi license to display the preprint in perp anse .	s preprint etuity.		
Eligibility screen	Х				
Informed consent	Х				
Allocation			Х		
CONDITIONS:					
ADAPT*			Х		
Waitlist			Х		
ASSESSMENTS:					
fMRI		Х		Х	
Pain and anxiety ratings		Х		Х	
Other study surveys	Х	Х		Х	

\*Aim to Decrease Anxiety and Pain Treatment (ADAPT) Figure 1

### Identification

Helen DeVos Children's Hospital Outpatient Clinics

A gastroenterology provider (physician or nurse practitioner) will confirm identification of eligible patients based on functional abdominal pain disorder (FAPD) diagnosis. The GI team will introduce the study to patients.



Further study eligibility measures (e.g., measures of anxiety) will be obtained either from the medical record or by study team. The research assistant will also assess MRI compatibility (e.g., claustrophobia screening and MRI safety screening) at patients' clinic visit or via phone/REDCap.

The patient will be queried for their current participation in psychological therapy for pain or anxiety.

## Neuroimaging screening

Participants' MRI visits will be scheduled

Baseline scans will be reviewed by radiologists for abnormalities prior to enrollment and randomization.

## Figure 2



# Figure 3



Figure 4